Shares of Hims & Hers (HIMS) are down $4.49, or 8%, to $53.51 near the open after Cigna (CI) said its drug benefit unit will cap out-of-pocket costs for weight-loss drugs at $200 a month for patients, which presents a cheaper cash-pay alternative to the telehealth platform’s offerings.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Hims & Hers growth moderated in April, says BofA
- Hims & Hers Health: Stabilizing Growth and Cautious Revenue Guidance Lead to Hold Rating
- Hims & Hers Health Issues $1 Billion in Notes
- Bullish flow in Hims and Hers Health (HIMS), with shares up $5.54 (+10.04%) near $60.76.
- Hims & Hers Stock (HIMS) Soars as Investors Ask ‘Boom or Bubble’?